Isolation and characterization of true mesenchymal stem cells derived from human term decidua capable of multilineage differentiation into all 3 embryonic layers

Macías, María Isabel; Grande, Jesús; Moreno, Ana Carolina Ramos; Domínguez, Irene; Bornstein, Rafael; Flores, Ana I.

doi:10.1016/j.ajog.2010.06.045

Cited by 105 publications

(111 citation statements)

References 65 publications

Supporting

Mentioning

108

Contrasting

Order By: Relevance

“…Thus, they may be a superior MSC source for clinical trials than the traditional source which is adult bone marrow. This section will focus on the isolation of MSC from amniotic fluid (Mareschi et al, 2009, Nadri and Soleimani, 2007, Roubelakis et al, 2007, the amniotic membrane (Soncini et al, 2007, Portmann-Lanz et al, 2006, Diaz-Prado et al, 2010, the chorion (chorion laeve and chorionic villi) (Soncini et al, 2007, Portmann-Lanz et al, 2006, Igura et al, 2004, Poloni et al, 2008, the decidua (Macias et al, 2010, Aghajanova et al, 2010, umbilical cord/Wharton's jelly (Mitchell et al, 2003, Reinisch et al, 2007, Petsa et al, 2009) and umbilical cord blood (Mareschi et al, 2001, Bieback et al, 2004, Romanov et al, 2003. This section will also discuss the isolation of haematopoietic stem cells from the umbilical cord blood and the application of these cells.…”

Section: Other Gestational Tissue Sources Of Mscmentioning

confidence: 99%

Exploring the Human Term Placenta as a Novel Source for Stem Cells and their Application in the Clinic

Heazlewood¹,

Cook²,

Ilić³

et al. 2012

Recent Advances in Research on the Human Placenta

View full text Add to dashboard Cite

Section: Other Gestational Tissue Sources Of Mscmentioning

confidence: 99%

Exploring the Human Term Placenta as a Novel Source for Stem Cells and their Application in the Clinic

Heazlewood¹,

Cook²,

Ilić³

et al. 2012

Recent Advances in Research on the Human Placenta

View full text Add to dashboard Cite

“…An important issue in using MSCs is their safety. Although some studies supported that there is a risk of MSCs malignant transformation [36,37] , several recent studies using different types of MSCs supported that there is neither in vitro risk of development chromosomal aberrations after long term culture nor in vivo induction of tumors [30,32,38,39] . For IBD treatment it is essential to increase the number of cells that migrate and home in to the intestine.…”

Section: Mesenchymal Stem Cell Transplantationmentioning

confidence: 99%

“…In addition, like Flores AI et al . Stem cell in inflammatory bowel disease bone marrow MSCs, placenta-derived MSCs are nonimmunogenic and immunomodulatory stem cells with high expansion and differentiation capacity [32][33][34][35] . An important issue in using MSCs is their safety.…”

Section: Mesenchymal Stem Cell Transplantationmentioning

confidence: 99%

“…For this reason, in the last few years the search for alternative tissue sources for MSCs has become of vital importance. Placental tissues, both fetal (amniotic fluid, Wharton's jelly, amniotic membrane, chorionic villi) and maternal (decidua) represent an important source of MSCs with some advantages including the isolation of large number of cells in a non invasive way [32,33] . In addition, like [32][33][34][35] .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?

Flores¹

2015

WJSC

View full text Add to dashboard Cite

Inflammatory bowel diseases are inflammatory, chronic and progressive diseases of the intestinal tract for which no curative treatment is available. Research in other fields with stem cells of different sources and with immunoregulatory cells (regulatory T-lymphocytes and dendritic T-cells) opens up new expectations for their use in these diseases. The goal for stem cell-based therapy is to provide a permanent cure. To achieve this, it will be necessary to obtain a cellular product, original or genetically modified, that has a high migration capacity and homes into the intestine, has high survival after transplantation, regulates the immune reaction while not being visible to the patient's immune system, and repairs the injured tissue. Core tip: Inflammatory bowel diseases are inflammatory, chronic and progressive diseases of the intestinal tract. A limited experience is available with hematopoietic and mesenchymal stem cell transplantation for the treatment of these conditions. Research is ongoing with other cell lines which have been used in conditions alike to inflammatory bowel disease and which will possibly have a therapeutic role in this condition. INTRODUCTIONInflammatory bowel disease (IBD) mainly consists of two clinical conditions, Crohn's disease (CD) and ulcerative colitis (UC). It is mainly characterized by chronic, destructive inflammation of the gastrointestinal tract for which no curative treatment is currently available.Its etiology is unknown, but it is accepted that it could be the result of loss of tolerance to intraluminal bowel antigens [1] . Genetic, environmental, and microbiological factors are involved in its development, Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?Ana I Flores, Gonzalo J Gómez-Gómez, Ángeles Masedo-González, M Pilar Martínez-Montiel together with morphological and functional changes in the intestinal barrier associated to an impaired immune response [2] . Early data supporting genetic involvement in the pathogenesis of IBD come from familial clinical studies showing a greater incidence in twins [3,4] , first-degree relatives [5,6] and given ethnic groups [7,8] . Genome-wide association scan studies have allowed for identification of more than 163 loci associated to IBD [9] , 73 genes associated to CD and 47 to UC [10] , and overlapping genes for both conditions have also been found [11] . Genetic factors would however account for less than 25% of cases [12] . The exception is represented by a monogenic disorder referred to as IBD-like diseases, which are associated with severe colitis in childhood and have at most three loci alternatives [13] . On the other hand the increase of the incidence of IBD suggests that environmental factors are more important than genetic factors in the development of IBD [14] . Since IBD etiology is currently unknown, current treatment is intended to control the inflammatory intestinal process, thus avoiding irreversible structural damage. However, current therapeutic results are di...

show abstract

“…This differentiation capacity as well as their immunosuppressive and immunomodulatory properties makes MSCs a very attractive resource for tissue regeneration . Bone marrow MSC are the most used cells in both experimental and clinical settings, although MSCs have been isolated from numerous sources such as adipose tissue, umbilical cord blood, umbilical cord tissue, amniotic fluid and placenta (Broxmeyer et al, 2006;De Coppi et al, 2007;Igura et al, 2004;Macias et al, 2010;Miki et al, 2005;Sarugaser et al, 2005;Soncini et al, 2007;Tallone et al, 2011).…”

Section: Adult Stem Cellsmentioning

confidence: 99%

Biomarkers, Stem Cells and Esophageal Cancer

Vegh¹,

Flores²

2012

Esophageal Cancer - Cell and Molecular Biology, Biomarkers, Nutrition and Treatment

View full text Add to dashboard Cite

Isolation and characterization of true mesenchymal stem cells derived from human term decidua capable of multilineage differentiation into all 3 embryonic layers

Cited by 105 publications

References 65 publications

Exploring the Human Term Placenta as a Novel Source for Stem Cells and their Application in the Clinic

Exploring the Human Term Placenta as a Novel Source for Stem Cells and their Application in the Clinic

Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?

Biomarkers, Stem Cells and Esophageal Cancer

Contact Info

Product

Resources

About